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Objective: To evaluate the risk of vulvar vestibulitis syndrome (VVS) associated with genital infections in a
case–control study.
Methods: Diagnosed cases with VVS (n = 69) and age-frequency-matched healthy controls (n = 65) were
enrolled from gynecology clinics in a university medical hospital during 1999. They were compared for potential
risk factors and symptoms of disease.
Results: VVS cases had a significantly higher risk of physician-reported bacterial vaginosis (BV) (odds ratio,
OR = 9.4), Candida albicans (OR = 5.7), pelvic inflammatory disease (PID) (OR = 11.2), trichomoniasis
(OR = 20.6), and vulvar dysplasia (OR = l5.7) but no risk associated with human papillomavirus (HPV), ASCUS,
cervical dysplasia, genital warts, chlamydia, genital herpes or gonorrhea. Genital symptoms reported significantly
more often with VVS included vulvar burning(91 vs. 12%), dyspareunia (81 vs. 15%), vulvar itching (68 vs. 23%)
and dysuria (54 vs. 19%) (p <  0.0001).
Conclusion: A history of genital infections is associated with an increased risk of VVS. Long-term follow-up
case–control studies are needed to elucidate etiologic mechanisms, methods for prevention and effective
treatment.
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The prevalence of vulvar vestibulitis syndrome
(VVS) has been estimated to affect approximately
15%oftheadultfemale populationwhoareseen in
gynecologic practices1,2. The condition has been
defined by the International Society for the Study
of Vulvar Disease (ISSVD) according to the
following criteria: (1) severe pain on vestibular
touch or vaginal entry; (2) tenderness on pressure
localizedwithinthevulvarvestibule; and(3)physi-
cal findings of erythema confined to the vesti-
bule2,3. VVS is an inflammatory process of the
vestibule of the vagina that involves the mucous
membrane and its underlying appendages, the
vestibular ducts and glands. Vestibular pain may
develop gradually or suddenly, followed by
pain-free periods1,4.
Characterized asthemost frequentcause ofdys-
pareunia, VVS is under-diagnosed, multi-factorial
and complex. Patients present with unexplained
pain,burning,stingingandrawnesslocalizedtothe
vulvar area1,5. Vestibulitis patients often are
misdiagnosed with a psychological condition
rather than physically based disease1. Previous
studies have provided inconclusive evidence into
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Clinical study 193the etiology of VVS. Some studies propose that
genital infections such as chronic candidiasis, her-
pes simplex virus (HSV), human papillomavirus
(HPV), contact dermatitis, irritants or vulvar
trauma cause VVS, but the findings have been
contradictory6–12. It has been postulated that
specific microflora may induce injury to the vesti-
bular nerve endings that leads to the extreme pain
as well as alterations in the immune system13,14.
Several studies also have suggested that there is a
hormonal component that increases the risk of
developing the syndrome possibly by altering
the quality or quantity of mucus secretions in the
vestibular glands, reducing the protective effect of
the vestibule10. The purpose of this epidemiologic
studywasto evaluate the role ofpathologicvaginal
microbial and viral agents as risk factors for VVS
among women diagnosed in a vulvar disease clinic
and a group of healthy women without this diag-
nosis at a university hospital tertiary care center.
METHODS
Population
Patients with VVS were recruited from the Vulvar
Disease Clinic at the University of Iowa Hospitals
and Clinics (UIHC). The clinic sees in excess of
2500 patients with vulvar and vaginal complaints
each year. Cases were recruited during two
time-periods between August and September and
Octoberand November 1999. Patients were diag-
nosedas havingVVS if theyhadtheISSVDcriteria
as described above. Since not all of the patients
were newly diagnosed with the disease, they did
notallcurrentlyhave all thesecriteriaat thetimeof
interview. One woman was excluded because she
did not complete the questionnaire, providing a
sample size of 69 cases (98.6% participation).
Between December 1999and May2000,a control
group ofwomen whohad never had a diagnosis or
any symptoms of VVS were solicited from general
gynecology clinics in the UIHC (n = 65) where
they were having annual exams. They were com-
pared with the VVS cases for risk-factor history
(98.5% participation). A single physician who has
diagnosed and treated the condition for approxi-
mately 20 years at the University of Iowa clinics
diagnosed all cases (Rudolph Galask). He and two
other physicians in the obstetrics/gynecology
department served as resources for recruiting
control subjects who were seeking routine
gynecologic care. The controls were matched to
cases basedonage-frequencyat 2-yearintervals. At
thetime ofenrollment, controlswere diagnosed as
being free of VVS and having no prior history of
thecondition.Patientssignedaninformedconsent
form (approved by the Human Subjects Review
Board thatoversees medicalresearch at theuniver-
sity) priorto enrolling in thestudy and completing
the questionnaire. One case and one control
declined participation in the study; thus the final
samplesizeincluded69VVScasesand65controls.
Procedures
With the exception of Pap smears and HPV DNA
testing, the diagnoses of genital infections and
related diseases were those from the referring
physician and a review of themedical chart among
those who were patients of the university hospital.
HPV testing was performed at the time of their
clinic and enrollment into the study. Patients
underwent one additional swab to test for HPV
DNA during their routine gynecological exam.
The HPV specimen was collected immediately
following the Pap smear using a cotton tip
applicator.Cellsfromthevulvarandvaginalregion
were placed in a sterile tube of saline, centrifuged
andfrozenat-70°Cforstorageuntilthelaboratory
assessment was conducted. The HPV DNA
specimens were evaluated by PCR amplification
followed by DNA sequencing in the HPV labs
where these tests are performed routinely using
standardized techniques for other research
protocols15.
Questionnaire and genital infection reports
Patients completed a 10-minute self-administered
risk-factor questionnaire at the time of enrollment
in the study. The research staff reviewed the
questionnaire and queried unanswered questions.
Informationfocusedonsociodemographiccharac-
teristics, sexual behavior and pregnancy history,
steroid hormone use (oral contraceptives (OCs)
and other sex steroid hormones), gynecological
history, alcohol and smoking exposure, history of
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its treatment. Responses were validated using
the patients’ medical records. Cases and controls
completed the same questionnaire except controls
omitted sections related to some of the VVS
symptoms. The research personnel completed a
gynecological history from which they elicited
information to verify a diagnosis and date of VVS,
gynecologic treatment for the disease, irritants of
VVS and other gynecological history to substan-
tiate patient statements about steroid hormone
use, sexual history, disease symptoms, genital
infections, history of genital warts, abnormal Pap
smears, genital dysplasia and invasive cancer, and
other genital conditions or diseases. The basis for
reporting vulvar intraepithelial neoplasia (VIN)
was from the university pathology report and that
of the gynecologist pathologist at the hospital.
Candidiasis was evaluated separately from reports
of yeast infection using the medical record since
this specific infection has been the focus of several
studies of VVS.
Data analysis
Comparisons between cases and controls for
ontinuous variables were examined using the
Wilcoxonranksumtest.Significanceofrisk factors
after adjusting for age was based on the Wald
statistics from the unconditionallogistic regression
models. Ninety-five percent confidence intervals
(CI) for age-adjusted odds ratios (OR) for disease
were calculated using the standard errors from the
corresponding logistic regression models and the
normal approximation. In comparisons where
there was a single zero cell count, age-adjusted
analyses were not performed. Instead, the Fisher’s
exact test was used to test the association between
vestibulitis and the genital infections and a correc-
tion of 0.516 was added to each cell count to
estimate the crude OR for disease and the corre-
sponding95%CI. Allcalculationswere conducted
using the SAS statistical package17.
RESULTS
Demographic characteristics
Characteristics of the study population are pre-
sented in Table 1. VVS cases were somewhat
youngeronaverage than were controls.Therewas
no statistically significant difference in income or
educational levels between cases and controls
although diagnosis of VVS was more likely to
occur with increasing income (Table 1). Com-
pared with married women, other marital status
groups were actually at lower risk of VVS. There
was no association between smoking or alcohol
and risk of disease. All of the cases and 92% of
the controls were non-Hispanic white (data not
shown).
Sexual behavior/hormone use
Most patients were heterosexual (97% cases vs.
92% controls) with a few bisexual (3 vs. 4%) or
homosexual(0 vs. 4%). Amongcases, 6.1% (n = 4)
stated that they never had sexual intercourse
compared to 4% (n = 1) of controls. Few VVS
women (12%) had changed sexual partners since
the onset of their symptoms. The majority of
partners reported no symptoms such as itching,
irritation, burning or other indication of an
infectious agent. The mean age at first intercourse
was similar between cases and controls (Table 2).
Age-adjusted risks indicate that older age at first
intercourse increased the risk of VVS more than
twofold. Nulliparity also was associated with a
significant increased risk whereas use of OCs
showed a nonsignificant protective effect against
VVS. Nine of 29 parous VVS cases had symptoms
prior to and during pregnancy. Use of sex
hormonesotherthan OCs also was associated with
a slightly elevated nonsignificant risk of disease.
Genital infections
Most of the infectious diseases (Table 3) were
reported more frequently in the VVS group.
Exceptions included a history of ASCUS and
cervical dysplasia, which are known to be
increased in the presence of past and current HPV
infection.Incontrast,reportsofapriordiagnosisof
vulvar dysplasia, which is associated with HPV
infection in younger-aged women, were found in
10% of the case group but not at all in controls. A
history of genital warts, which is caused by
non-oncogenic HPV types, was reported slightly
more frequently in VVS cases but the difference
VVS risk and infections Smith et al.
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was no association between current HPV status
and historical reporting of these HPV-related
diseases. Furthermore, none of the patients had an
HPV-related disease at the time of enrollment. A
number of other microflora were also associated
with an increased risk of vestibulitis: candidiasis,
trichomoniasis, bacterial vaginosis (BV) and pelvic
VVS risk and infections Smith et al.
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Sexual behavior/hormone use Cases Controls p-value Age-adjusted OR (95% CI)
Mean age at first intercourse,
years (range)
<18
‡ 18
Currently having sex
Number of pregnancies
0
‡ 1
OC use
Never
No longer
Current
Use of other hormones
18.9 (14–28)
n (%)
22 (34.9)
41 (65.1)
57 (87.7)
40 (58)
29 (42)
9 (13)
26 (37.7)
34 (49.3)
22 (31.9)
18.2 (13–30)
n (%)
30 (50)
30 (50)
49 (77.8)
19 (29.2)
46 (70.8)
5 (7.7)
39 (60)
21 (32.3)
18 (27.7)
0.18
—
0.02
0.33
< 0.01
—
—
0.1
0.67
0.19
—
1
2.3 (1.1–4.9)
1.5 (0.7–3.6)
3.3 (1.4–7.6)
1
1
0.4 (0.1–1.2)
0.7 (0.2–2.8)
1.7 (0.8–4)
CI, confidence interval; OC, oral contraceptive; OR, odds ratio; VVS, vulvar vestibulitis syndrome
Table 2 Sexual behavior and sex steroid hormone use of VVS cases and controls
Demographic characteristic Cases (n = 69) Controls (n = 65) p-value Age-adjusted OR (95% CI)
Mean age, years (range)
Mean education, years (range)
Income, n (%)
< $20 000
$20 000–39 999
$40 000–59 000
‡ $60 000
Marital status, n (%)
Married
Single
Separated/divorced
Smoking, n (%)
Never
Given up
Current
Alcohol, n (%)
Never
Given up
Current
33 (19–63)
15.3 (10–21)
9 (13)
17 (24.6)
21 (30.4)
20 (29)
47 (68.1)
17 (24.6)
5 (7.3)
53 (76.8)
10 (14.5)
6 (8.7)
35 (50.7)
12 (17.4)
22 (31.9)
36 (21–65)
15.9 (12–21)
10 (15.4)
22 (33.9)
15 (23.1)
18 (27.7)
38 (58.5)
16 (24.6)
11 (16.9)
46 (70.8)
9 (13.9)
10 (15.4)
22 (33.8)
15 (23.1)
28 (43.1)
0.05
0.19
—
0.68
0.08
0.08
—
0.2
0.054
—
0.73
0.31
—
0.93
0.09
—
—
1
1.3 (0.4–4)
3.1 (0.9–10.7)
3.3 (0.9–12.1)
1
0.6 (0.2–1.4)
0.3 (0.1–1)
1
1.2 (0.4–3.3)
0.6 (0.2–1.7)
1
1 (0.4–2.5)
0.5 (0.2–1.1)
CI, confidence interval; OR, odds ratio; VVS, vulvar vestibulitis syndrome
Table 1 Demographics, sexual behavior and physician-diagnosed genital diseases of VVS cases and controlsinflammatory disease (PID). There was no differ-
ence in risk between VVS cases and controls for
gonorrhea, syphilis or vaginal dysplasia.
Other medical conditions
Patients were queried about some other diseases
that have been reportedly higher in VVS patients,
and which may be related to immunologic alter-
ations or other unknown factors causative in the
development of vestibulitis. The findings suggest
that most of these were found more often in VVS
cases than in controls: upper respiratory infections
(URIs), muscle aches not related to some other
specific medical condition, immunodeficiency
diseases, increased tiredness and poor wound
healing (Table 3).
Symptom characteristics
On average, approximately2years passed between
thetimeofinitialsymptomsanda correctdiagnosis
ofthedisease. Theaverage time between diagnosis
and time of interview among the participating
cases was 4.9 years. Only 21% of the cases were
diagnosed within6 monthsand 36% within 1year.
After 3 years, 75% of cases had received a correct
clinical diagnosis but it was not uncommon for
patients to remain undiagnosed for 12 or more
years. At the time of enrollment in the study,
which would have occurred several years after
initial diagnosis, patients were asked to describe
their current symptom status. Over half (53%) of
the patients had intermittent symptoms. A large
percentage (43%) still had constant, persistent
symptoms compared with the time of diagnosis
VVS risk and infections Smith et al.
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Medical condition Cases n (%) Controls n (%) p-value Age-adjusted OR (95% CI)
Genital infections/diseases
HPV infection
ASCUS
Cervical dysplasia
Vulvar dysplasia*
Vaginal dysplasia
Genital cancer
Genital warts
Yeast infection*
Candidiasis
Trichomoniasis*
Bacterial vaginosis
Chlamydia
Pelvic inflammatory disease*
Genital herpes
Gonorrhea
Syphilis
Other conditions
Upper respiratory infections
Muscle aches
Immunodeficiency disease*
Increased tiredness
Poor wound healing
18 (26.1)
10 (14.5)
11(15.9)
7 (10.1)
0 (0)
0 (0)
7 (10.1)
29 (42)
15 (21.7)
9 (13)
8 (11.6)
6 (8.7)
5 (7.3)
3 (4.4)
1 (1.5)
0 (0)
29 (42)
21 (30.4)
4 (5.8)
27 (39.1)
4 (5.8)
18 (27.7)
17 (26.2)
18 (27.7)
0 (0)
0 (0)
0 (0)
4 (6.2)
0 (0)
3 (4.6)
0 (0)
1 (1.5)
6 (9.2)
0 (0)
5 (7.7)
2 (3.1)
0 (0)
15 (23.1)
8 (12.3)
0
7 (10.8)
1 (1.5)
0.75
0.09
0.1
0.01
—
—
0.4
< 0.0001
< 0.01
< 0.01
0.03
0.91
0.06
0.48
0.61
—
0.03
< 0.01
0.12
< 0.01
0.21
0.9 (0.4–1.9)
0.5 (0.2–1.1)
0.5 (0.2–1.2)
15.7 (0.9–281)
—
—
1.9 (0.5–6.9)
95.4 (5.7–1604)
5.7 (1.5–21)
20.6 (1.2–361)
9.4 (1.1–79)
1 (0.3–3.3)
11.2 (0.6–206)
0.6 (0.1–2.6)
0.6 (0.05–7)
—
2.4 (1.1–5)
3.8 (1.5–9.9)
9 (0.5–170)
5.6 (2.2–14.4)
4.3 (0.4–40.6)
*Adjusted for 0.5 correction factor due to ‘0’ count in cell – age-adjusted rates could not be determined; CI, confidence interval; HPV,
human paillomavirus; OR, odds ratio; VVS, vulvar vestibulitis syndrome
Table 3 Physician-diagnosed genital infections and other medical conditions of VVS cases and controlsbut they felt better than at the onset of the initial
symptoms. A small number of women reported
suffering constant symptoms that never improved
(Table 4).
Compared with women without the disease,
VVS cases at the time of interview were more
likely toreportmultiplegenitalsymptomswith the
exceptionofrectalpain(Table4).AllVVSpatients
reported some pain at the time of diagnosis. The
most frequently cited symptoms in the VVS
patients were vulvar burning (91%) and dys-
pareunia (81%) whereas the most frequently
reported symptom in controls was that of vulvar
itching (23%). Other symptoms specifically
associated with VVS included discharge, which
was most frequently white (55%), clear (40%) or
yellow (40%) in color. During symptomatic
periods, 93.3% of cases had discharge while during
non-symptomatictimes, 69.6% still reported some
discharge. Theconsistency of thedischarge during
symptomatic periods varied within patients and
was most often reported as mucosy (70%), watery
(37%) and/or cheesy (12%). Most cases described
the amount of discharge from light (52%) to
moderate (40%) and many noticed an odor to the
discharge (43%). Among those who were receiv-
ing treatment for VVS at the time of enrollment,
the most common drugs used were an A&D oint-
ment (25%), nystatin-triamcinolone ointment/
mycolog (23%), baking soda soaks (12%), tri-
amcinolone ointment (8%) and hydrocortisone
ointment (8%). None of the patients received
surgical treatment.
Incident versus prevalent cases
Women who were considered incident cases
(21%) based on having initial symptoms and diag-
nosis within 6 months showed some differences in
symptomotology compared to the prevalent cases
(79%). There were few differences between the
incident and prevalent cases by demographic or
sexual behavior characteristics previously des-
cribed in Tables 1 and 2. Newly diagnosed cases
were more likely than previously diagnosed
women to be former (67 vs. 17%, p < 0.01), but
not current, alcohol users. Incident cases were less
likely to have been aged 18 years or older at first
intercourse (25 vs. 35%) and more likely to be
current users of OCs (64 vs. 48%), but the signifi-
cance in relation to disease is unclear. Incident
cases were more frequently told they had vulvar
dysplasia (21 vs. 8%), and cervical dysplasia (21 vs.
15%) but were less commonly diagnosed with
genital warts (0 vs. 13%) – all diseases related to
HPV infection. They also were more commonly
diagnosed with candidiasis than were prevalent
cases (40 vs. 17%). Other microflora shown in
Table 3 were not different in frequency between
the two case groups. Incident cases were less likely
to have prediagnostic symptoms of vulvar burning
(79 vs. 94%) or itching (57 vs. 73%), clitoral pain
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Symptoms Cases n (%) Controls n (%) p-value Age-adjusted OR (95% CI)
Constant: never better*
Constant: better, but persist*
Intermittent*
Vulvar burning
Vulvar itching
Dysuria
Frequent urination
Urgent urination
Clitoral pain
Rectal pain
Dyspareunia
3 (4.4)
29 (42.7)
36 (52.9)
63 (91.3)
47 (68.1)
37 (53.6)
31 (44.9)
32 (46.4)
29 (42)
9 (13)
56 (81.2)
8 (12.3)
15 (23.1)
12 (18.5)
12 (18.5)
9 (13.9)
1 (1.5)
5 (7.7)
10 (15.4)
—
—
—
< 0.0001
< 0.0001
< 0.0001
< 0.001
< 0.0001
< 0.0001
0.31
< 0.0001
—
—
—
73.4 (23.7–227)
6.8 (3.1–14.6)
4.9 (2.2–10.8)
3.6 (1.6–8)
5.3 (2.2–12.4)
45.7 (6–350)
1.8 (0.6–5.7)
23 (9.3–57)
*Questions appropriate for VVS only; CI, confidence interval; OR, odds ratio; VVS, vulvar vestibulitis syndrome
Table 4 VVS-related symptoms prior to diagnosis or clinic visit(29 vs. 46%) or rectal pain (7 vs. 15%). There was
nodifferenceinreportingdyspareunia(85 vs. 83%)
or dysuria (50 vs. 56%).
DISCUSSION
This investigation found that VVS patients had a
history of genital infections and diseases signifi-
cantly more often than a group of healthy women.
Itisunlikelythatthese differencescanbeexplained
strictly on thebasis of selection bias since almost all
solicited women agreed to participate in the study.
The review of medical and pathology reports to
verify statements minimized any recall bias of
patient self-reports. However, because lab results
were not available for every event, it would be
important to clarify whether these infections
occurred at a different frequency in newly diag-
nosed (incident) cases, whether infection rates
were higher in VVS because most were prevalent
casesreportingratesbasedonbothinitialinfections
as well as subsequent events, and whether the
frequency of infections was truly higher than
reported by asymptomatic controls. In this study
we found that most microflora and genital
conditions were not reported at a different fre-
quency between the incident and prevalent case
groups, suggesting there was not bias in reporting
more infections among prevalent cases. Physician
bias associated with knowledge of a prior VVS
diagnosis may have led to a higher frequency of
evaluation and diagnosis of microflora in previous
studies. We were not able to examine this issue in
our cross-section of cases and controls but further
assessment, by following diseased and healthy
women and periodically performing the same
clinical and laboratory assessments, is warranted.
Future epidemiologic research should evaluate
risks in incident cases and follow them at subse-
quent intervals to characterize the natural history
and risks of the disease. It is unknown whether
there are differences in etiology between those
whorecoverfromVVSand thosewhocontinueto
havesymptoms.Based onthefrequentlackofearly
diagnosis of VVS, patients may spend several years
with the disease prior to a definitive diagnosis.
Because of the long average duration of symptoms
and the nature of the condition as one of unspeci-
fied persistence, prevalent cases that have been
symptomatic forsome time – regardless of the date
of diagnosis – may represent groups with different
etiologic risk factors. Prevalent cases of VVS also
may have differential recall of symptoms because
they have them more often over the course of the
disease than newly diagnosed cases. Our investi-
gation foundthatprevalent cases didrecall a higher
frequency of a number of VVS-related symptoms
although not those that occur most commonly in
incident cases, dyspareunia or dysuria.
An unexpected finding in this study was the
frequency of vulvar dysplasia among VVS patients
in contrast to its complete absence in controls. All
werediagnosedat thetimeofVVS diagnosisbythe
same study gynecologist (Rudolph Galask). The
incidence of VIN is low (3/105) among those
belowtheageof35,theagegroupconsideredtobe
at highest risk of VVS18. Seven of the VVS patients
had a history of dysplasia at the time of study
enrollment; thus over 40 patients/year would be
expected to be diagnosed with VVS/vulvar
dysplasia simultaneously at the vulvar clinic. That
translates into 10% of cases of VVS cases having a
diagnosis of vulvar dysplasia per year – women
who might have developed cancer if not for their
VVS symptoms. In support of a possible causal
association, the presence of HPV oncogenic types
is associated with risk of VIN in younger, but not
older, women19,20. Since all the patients in our
investigation weretreated priortotestingforHPV,
the lack of association between the current HPV
resultandvulvar dysplasiawasnotunexpected.Itis
possible that HPV is a risk for both VIN and VVS.
In previous studies, the association between VVS
and HPV has been inconsistent, with detection in
between 5 and 100% ofcases6–11. Whereas Prayson
and colleagues6, in a study of 36 women with
vestibulitis, revealed no positive results for HPV
types 6, 11, 16, 18, 31 or 35 using DNA in situ
hybridization, Costa and colleagues21 detected
80% of cases with HPV 16/18 (oncogenic viral
types) using Southern blot. Bornstein and
colleagues8 detected HPV in 54% of cases butonly
4%ofcontrols,usingPCR/hybridizationtodetect
HPV 6, 11, 16, 18 and 33, most of which were
HPV 16 and 18. When examining other risks and
confounders of VVS, comparing the HPV+ and
HPV- cases, they found no differences in OC
use, parity, age, education, smoking or medically
VVS risk and infections Smith et al.
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colleagues22 detected HPV in 29.6% of vestibulitis
cases and 23.9%ofcontrolsby PCR/hybridization
capture assay – rates that are similar to those found
in this study. Further, 17% of the cases and 16.1%
of controls in their study had high-risk HPV
whereas we detected oncogenic types in 14.5%
of VVS and 18.5% of healthy women. The wide
range of HPV frequency foundin different studies
may be explained by failure to include a control
group,toincludealargernumberofolderwomen,
to use different, less sensitive lab techniques or
to include a wide variety of HPV oncogenic
types for assessment. Ideally, detection of HPV
infection should be performed prior to treatment
for dysplasia or VVS and then subsequently
reevaluated in conjunction with disease status and
symptoms.
It is unclear why the healthy controls in this
study had much higher rates of two other diseases,
ASCUS and cervical dysplasia, since they were
recruited from private staff practices, nothigh-risk
clinics. HPV infection is associated with only a
small portion of those who are diagnosed with
these diseases and may explain why there was no
association between a history of these conditions
and current HPV status. Treatment also may
explain this lack of association. AlthoughHPV has
been linked to VVS, there have been no previous
reports of an association between these cervical
conditions and VVS disease. This inconsistent
association may be due to greater vulnerability of
the epithelia of women with vestibulitis to (HPV)
infection rather than a causal association between
HPV and VVS.
Theincreased prevalence of othergenital infec-
tions,including yeast infections12, candidiasis3,12,23,
trichomoniasis12,BV12,PID12andgenital herpes12,
has been found in some but not all previous
investigations of microflora and vestibulitis. A
history of candidiasis is one of the more consis-
tent infections detected at a higher rate in these
women. Sarma12, in a small case–control study,
also reported BV and yeast infections more
frequently in VVS patients but not trichomoniasis
or PID as found in this investigation. One possible
explanation for the differences in findings may
be attributable to our review of prior medical
and pathology lab results or referring physician
statements of genital infections to corroborate
patient reports of infections and diseases. Other
conditions examined in this study – vaginal
dysplasia, gonorrhea and syphilis – have not been
characterized in other research. Based on our data,
thesewouldappeartopresentnorisk inassociation
with vestibulitis.
Although our VVS cases were somewhat
younger on average than were controls, both the
average and range of ages were comparable to
reports found in other studies5,6. There were no
significant changes in findings for demographics,
sexual behavior, genital diseases or symptoms
between crude and reported age-adjusted rates.
Because VVS was more frequently diagnosed with
increasing income,thecharacteristicsofthepatient
populationmay be biased towards those who have
greater financial access to health care. However,
educational level, a more significant indicator of
health care behavior, did not differ between cases
and controls. Our VVS patient population mirrors
that of other studies in regard to race, namely that
Caucasians are the predominant racial group to
present with this condition1,12. Whether this is a
reflection ofsocioeconomicstatus ordifferencesin
predisposition to risk is unclear. The fact that a
higher frequency of VVS patients were married,
currently having sex and using OCs may be
indicative of a greater risk of exposure to STDs.
Compared with healthy women, those with VVS
did indicate significantly higher rates of genital
discomfort and pain, particularly dyspareunia (81
vs. 15%, p < 0.0001) and clitoral pain (42 vs. 2%,
p < 0.0001). These findings related to sexual
behavior also contradict the belief that patients
with this condition avoid sexual contact because
of a high rate of pain1,5. It must be remembered,
however, that the average duration until diagnosis
in the VVS group was 2 years and several more
years until the time of the study, by which time a
large percentage of patients noted that their
symptoms were better or intermittent.
Several studies have postulated that the under-
lying factor important in the development of this
disease is related to theimmune system14. An alter-
ation in the immune system of VVS patients is
supported not only by the higher risk of genital
infections but also that of URIs, immuno-
deficiency diseases, and musculoskeletal problems,
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Ashman and Ott23 hypothesized that auto-
immunity may play a role in vestibulitis risk. They
propose that in susceptible individuals, antigens
of candida are cross-reactive with certain vulvo-
vaginaltissueantigens,thuspreventingan effective
immune response, and that after repeated infec-
tions the immune system becomes hyper-reactive
against these cells. These responses could be
triggered by hormonal changes or use of OCs. In
support of this hypothesis, Bornstein8 found an
association between vestibulitis and use of OCs.
Our case population also had a higher rate of
candida infection, current use of OCs and use of
other sex steroid hormones.
Biopsy studies of tissue from women with
vestibulitis haveshownlocalchronicinflammatory
reactions6. Foster and colleagues26 demonstrated
that vulvar biopsies from women with vestibulitis
also had higher levels of interleukin-1 (IL-1) and
tumor necrosis factor alpha (TNFa) than controls.
These findings are consistent with the data of
Chadha and colleagues27 who examined punch
biopsies fromthevulvar vestibule ofVVS cases and
age-matched controls. They found chronic
inflammatory infiltrate present in all specimens
with VVS, which consisted primarily of T
lymphocytes and a small percentage of B cells,
plasma cells and mast cells. In a preliminary study
evaluating sera for NK cell activity to determine
whether vestibulitis patients had alterations in
immune regulation22, we found that overall, cases
had significantly decreased NK cell activity
compared with age-matched controls, with an
average lytic level of 0.93 in VVS cases and 4.19 in
controls. While it is not possible to determine
whether the NK cells were decreased as a result
rather than a cause of the disease, one reasonable
interpretation is thatthecells migrated to thetissue
to combat infections.
Based on our findings and other clinical and
immunologic studies, there is further need to
examine immunological parameters in both the
blood and affected tissue to correlate findings with
the findings of various microfloral lab results. To
better understandetiologic and preventive mecha-
nisms of vestibulitis, potential microfloral risk
factors and immunologic markers need clarifica-
tion ina groupofdiagnosed VVS cases andhealthy
controls who receive similar diagnostic work-up
and who are followed over time for changes in
infection status, symptoms and recovery.
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